# A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects

> **NCT04651036** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** QL0605
- **DRUG:** US Neulasta

## Key facts

- **NCT ID:** NCT04651036
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-06
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04651036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04651036, "A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04651036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*